| ［1］ |
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（9）:1400⁃1412. DOI: 10.1002/art. 40930.
|
| ［2］ |
徐亮, 王元, 陈顺乐. 低剂量泼尼松治疗系统性红斑狼疮血小板减少的疗效观察［J］. 中华皮肤科杂志, 2005,38（6）:386⁃387. DOI: 10.3760/j.issn:0412⁃4030.2005.06.021.
|
| ［3］ |
龙现明, 蔡成森, 周欣, 等. 系统性红斑狼疮继发难治性血小板减少的临床特征分析［J］. 中华风湿病学杂志,2020,24（3）:170⁃174. DOI: 10.3760/cma.j.issn.1007⁃7480.2020.03.005.
|
| ［4］ |
Mahévas M, Michel M, Weill JC, et al. Long⁃lived plasma cells in autoimmunity: lessons from B⁃cell depleting therapy［J］. Front Immunol, 2013,4:494. DOI: 10.3389/fimmu.2013.00494.
|
| ［5］ |
Mahévas M, Azzaoui I, Crickx E, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial［J］. Haematologica, 2021,106（9）:2449⁃2457. DOI: 10.3324/haematol.2020.259481.
|
| ［6］ |
Shipa M, Embleton⁃Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus : a randomized controlled trial［J］. Ann Intern Med, 2021,174（12）:1647⁃1657. DOI: 10.7326/M21⁃2078.
|
| ［7］ |
Atisha⁃Fregoso Y, Malkiel S, Harris KM, et al. PhaseⅡ randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis［J］. Arthritis Rheumatol, 2021,73（1）:121⁃131. DOI: 10.1002/art.41466.
|
